Sun Pharma, the speciality pharma company has reached an agreement for the purchase of three niche brands from the San Diego, US-based Women's First Healthcare (WFHC). These brands had been offered for sale as a part of WFHC's Chapter 11 bankruptcy filing.
These brands are the synthetic antibacterial Bactrim (sulfamethoxazole with trimethoprim), the gynecological Ortho-Est (estropipate), and the antimigraine preparation Midrin (isometheptene, acetaminophen, dichloralphenazone). These brands have combined US annual sale of $ 7.6 million, release from Sun says.
Dilip Shanghvi, CMD, Sun Pharma says, "The acquisition of these US brands will help us understand brand promotion in the US at a low cost. In the past too, we have acquired assets at a low cost and created value. We are confident of unlocking the value that these brands offer."
Sun Pharma expects sales for some of these products to begin shortly, while some products have may larger inventory and it may take some time to commence sales.